LivaNova (NASDAQ:LIVN) Rating Increased to Strong-Buy at StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a strong-buy rating in a research report report published on Tuesday morning.

Other equities analysts have also recently issued research reports about the company. Stifel Nicolaus decreased their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 target price on shares of LivaNova in a research note on Monday, March 17th. Barclays reduced their price target on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a report on Friday, March 7th. Mizuho dropped their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Finally, Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, LivaNova currently has a consensus rating of “Buy” and a consensus price target of $61.17.

LivaNova Price Performance

NASDAQ LIVN opened at $39.92 on Tuesday. The company has a market cap of $2.17 billion, a PE ratio of 95.05 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova has a 52-week low of $36.85 and a 52-week high of $64.48. The firm’s 50 day moving average price is $45.01 and its 200-day moving average price is $48.65.

Institutional Investors Weigh In On LivaNova

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. grew its holdings in shares of LivaNova by 62.7% during the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after purchasing an additional 806,374 shares during the last quarter. Freestone Grove Partners LP acquired a new position in LivaNova during the 4th quarter valued at approximately $23,102,000. Artisan Partners Limited Partnership bought a new position in LivaNova during the 4th quarter worth $21,340,000. The Manufacturers Life Insurance Company increased its position in LivaNova by 163.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company’s stock worth $25,303,000 after buying an additional 339,139 shares during the period. Finally, AQR Capital Management LLC lifted its stake in LivaNova by 79.3% in the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company’s stock valued at $34,214,000 after buying an additional 328,313 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.